Wyeth

Medimmune Limited

Genetics Institute, Inc.

Laura L Carter

Mary Collins

Beatriz M Carreno

Clive R Wood

Caroline S Russell

Deborah P Luxenberg

John Edward Andrews

Frances K Bennett

Jason Jussif

Debra D Donaldson

Matthew James Whitters

Viia Valge-Archer

Deborah A Young

Michelle J Unger

Glenn R Larsen

Marion T Kasaian

Joann Witek

Vila Valge-Archer

Leslie D Lowe

Kyri Dunussi

Margery Ma

Lesile D Lowe

Caroline Russell

John Andrews

Joann S Witek

Michelle Ungar

This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.

Nucleic acids encoding antibodies against PD-1

Methods of upmodulating adaptive immune response using anti-PD-1 antibodies

Antibodies against PD-1

Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor ('IL-21R' or 'MU-1'), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

Methods and compositions for modulating interleukin-21 receptor activity

Provided is a method of suppressing an immune response in a subject by administering an antagonist of a MU-1 hematopoietin receptor superfamily chain protein.

Methods of treatment with antagonists of MU-1

Growing community of inventors

Medford, MA, United States of America

Laura L Carter